A 25-year-old Venezuelan male presented to a Chicago area emergency department (ED) in early November 2023. He had traveled with his family through Panama, Costa Rica, Nicaragua, Honduras, Guatemala, Mexico, and Texas before arriving in Chicago approximately one month prior to his ED visit. He noted spending about five days walking through a jungle, as well as traversing rivers. This was his third presentation to an area ED for the same complaint of a right forearm wound. It was initially treated with trimethoprim/sulfamethoxazole and cephalexin with no improvement. It was slightly painful but not pruritic. On presentation, a 4-cm wound was noted on his right forearm [Figure 1]. His daughter had two similar lesions on her right leg [Figure 2]. He also had multiple nodules along his forearm. The wound had been worsening for the last three weeks despite antibiotic treatment.
Explore This Issue
ACEP Now: Vol 43 – No 02 – February 2024There was concern for possible cutaneous leishmaniasis (CL), therefore he was admitted to the hospital for infectious-disease and surgical consultations, as well as to complete a punch biopsy the following day. He was discharged with followup at an outpatient wound care and a primary care clinic. Biopsy results were available to the care team 20 days later (after being sent to a Mayo Clinic) with confirmation of diagnosis of CL. At this time, consultation was made to infectious disease specialists, as well as the ED pharmacy team for assistance with treatment options. The patient was uninsured with limited resources, making miltefosine cost prohibitive. Paromomycin cream was not available in any local or regional pharmacies. The components for paromomycin cream are not FDA approved and are sourced from outside the U.S. on a case-by-case basis and sent to a compounding pharmacy in the area on behalf of the patient. The patient was able to receive the paromomycin cream from the compounding pharmacy, and has been following up with wound care. He is noting slow improvement in his wound.
What is Leishmaniasis?
Leishmaniasis is a vector-born protozoal disease transmitted by sand flies, considered to be endemic in 99 countries.1 Texas and Oklahoma have endemic levels of CL, but there is no endemic level in the northern United States.2 Globally, cases are most common in the Middle East, North Africa, Central America and northern South America. There may be 700,000 to 1.2 million cases of CL per year globally; however, CL is not a reportable disease to the CDC, so there is no reliable way to track U.S. cases.3 Historically, most cases diagnosed in the U.S. were related to military travel and deployment, with a few cases related to leisure travel. Leishmaniasis is an obligate intracellular parasite in mammals with an incubation period of weeks to months. CL is a spectrum of cutaneous disease ranging from localized to diffuse which result in ulcers, but no mucosal involvement.4 Leishmaniasis can also present as mucosal leishmaniasis (ML) and visceral leishmaniasis (VL) with ML being a metastatic sequela of CL years to decades later. VL is generally an acute process, incubating for weeks to months causing fever, weight loss, hepatosplenomegaly, pancytopenia, and an elevated serum protein level.5
Pages: 1 2 3 | Single Page
No Responses to “Case Report: Cutaneous Leishmaniasis in Chicago”